Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment

Low chemosensitivity considerably restricts the therapeutic efficacy of gemcitabine (GEM) in pancreatic cancer treatment. Using immunohistochemical evaluation, we investigated that decreased expression of human equilibrative nucleoside transporter-1 (hENT1, which is the major GEM transporter across...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomaterials 2018-03, Vol.158, p.44-55
Hauptverfasser:	Zhao, Xiao, Wang, Xiuchao, Sun, Wei, Cheng, Keman, Qin, Hao, Han, Xuexiang, Lin, Yu, Wang, Yongwei, Lang, Jiayan, Zhao, Ruifang, Zheng, Xiaowei, Zhao, Ying, shi, Jian, Hao, Jihui, Miao, Qing Robert, Nie, Guangjun, Ren, He
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Carcinoma, Pancreatic Ductal - drug therapy Cell Line, Tumor Deoxycytidine - analogs & derivatives Deoxycytidine - metabolism Deoxycytidine - pharmacology Equilibrative Nucleoside Transporter 1 - genetics Equilibrative Nucleoside Transporter 1 - metabolism Female Gemcitabine Gene Expression Regulation, Neoplastic hENT1 Humans Liposomes - chemistry Mice Nanocarriers Pancreatic ductal adenocarcinoma Precision Medicine - methods Ribonucleotide Reductases - genetics Ribonucleotide Reductases - metabolism RNA, Small Interfering - genetics RRM2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!